Extensive experience in its field

• Used in over 300 million patients around the world
• Available in over 100 countries
• Providing high quality contrast for more than 25 years
• Reported in over 6,500 published clinical articles

Omnipaque sets a standard for Low Osmolar Contrast Media (LOCM) as a class
• Both the ESUR, and analysis of data from reports to the FDA, group all LOCM together as a class when considering safety[1,3,8]
• The balance of clinical evidence demonstrates that Omnipaque has not been surpassed by other LOCM for either diagnostic efficacy or safety[1,9-22]

Representative clinical comparisons of other LOCM with Omnipaque
	superior diagnostic efficacy to Omnipaque?	superior safety to Omnipaque?
iopamidol[l,9-11]	no	no
iomeprol[12,13]	no	no
iopromide[13,14]	no	no
iobitridol[15,16]	no	no
ioversol[l,17,18]	no	no
ioxaglate[6,19-22]	no	no